Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 9

See more details

Referenced in 7 patents
54 readers on Mendeley
  • Article usage
  • Citations to this article (353)

Advertisement

Research Article Free access | 10.1172/JCI116066

Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.

K Aalto-Setälä, E A Fisher, X Chen, T Chajek-Shaul, T Hayek, R Zechner, A Walsh, R Ramakrishnan, H N Ginsberg, and J L Breslow

Laboratory of Biochemical Genetics and Metabolism, Rockefeller University, New York 10021, USA.

Find articles by Aalto-Setälä, K. in: JCI | PubMed | Google Scholar

Laboratory of Biochemical Genetics and Metabolism, Rockefeller University, New York 10021, USA.

Find articles by Fisher, E. in: JCI | PubMed | Google Scholar

Laboratory of Biochemical Genetics and Metabolism, Rockefeller University, New York 10021, USA.

Find articles by Chen, X. in: JCI | PubMed | Google Scholar

Laboratory of Biochemical Genetics and Metabolism, Rockefeller University, New York 10021, USA.

Find articles by Chajek-Shaul, T. in: JCI | PubMed | Google Scholar

Laboratory of Biochemical Genetics and Metabolism, Rockefeller University, New York 10021, USA.

Find articles by Hayek, T. in: JCI | PubMed | Google Scholar

Laboratory of Biochemical Genetics and Metabolism, Rockefeller University, New York 10021, USA.

Find articles by Zechner, R. in: JCI | PubMed | Google Scholar

Laboratory of Biochemical Genetics and Metabolism, Rockefeller University, New York 10021, USA.

Find articles by Walsh, A. in: JCI | PubMed | Google Scholar

Laboratory of Biochemical Genetics and Metabolism, Rockefeller University, New York 10021, USA.

Find articles by Ramakrishnan, R. in: JCI | PubMed | Google Scholar

Laboratory of Biochemical Genetics and Metabolism, Rockefeller University, New York 10021, USA.

Find articles by Ginsberg, H. in: JCI | PubMed | Google Scholar

Laboratory of Biochemical Genetics and Metabolism, Rockefeller University, New York 10021, USA.

Find articles by Breslow, J. in: JCI | PubMed | Google Scholar

Published November 1, 1992 - More info

Published in Volume 90, Issue 5 on November 1, 1992
J Clin Invest. 1992;90(5):1889–1900. https://doi.org/10.1172/JCI116066.
© 1992 The American Society for Clinical Investigation
Published November 1, 1992 - Version history
View PDF
Abstract

Hypertriglyceridemia is common in the general population, but its mechanism is largely unknown. In previous work human apo CIII transgenic (HuCIIITg) mice were found to have elevated triglyceride levels. In this report, the mechanism for the hypertriglyceridemia was studied. Two different HuCIIITg mouse lines were used: a low expressor line with serum triglycerides of approximately 280 mg/dl, and a high expressor line with serum triglycerides of approximately 1,000 mg/dl. Elevated triglycerides were mainly in VLDL. VLDL particles were 1.5 times more triglyceride-rich in high expressor mice than in controls. The total amount of apo CIII (human and mouse) per VLDL particle was 2 and 2.5 times the normal amount in low and high expressors, respectively. Mouse apo E was decreased by 35 and 77% in low and high expressor mice, respectively. Under electron microscopy, VLDL particles from low and high expressor mice were found to have a larger mean diameter, 55.2 +/- 16.6 and 58.2 +/- 17.8 nm, respectively, compared with 51.0 +/- 13.4 nm from control mice. In in vivo studies, radiolabeled VLDL fractional catabolic rate (FCR) was reduced in low and high expressor mice to 2.58 and 0.77 pools/h, respectively, compared with 7.67 pools/h in controls, with no significant differences in the VLDL production rates. In an attempt to explain the reduced VLDL FCR in transgenic mice, tissue lipoprotein lipase (LPL) activity was determined in control and high expressor mice and no differences were observed. Also, VLDLs obtained from control and high expressor mice were found to be equally good substrates for purified LPL. Thus excess apo CIII in HuCIIITg mice does not cause reduced VLDL FCR by suppressing the amount of extractable LPL in tissues or making HuCIIITg VLDL a bad substrate for LPL. Tissue uptake of VLDL was studied in hepatoma cell cultures, and VLDL from transgenic mice was found to be taken up much more slowly than control VLDL (P < 0.0001), indicating that HuCIIITg VLDL is not well recognized by lipoprotein receptors. Additional in vivo studies with Triton-treated mice showed increased VLDL triglyceride, but not apo B, production in the HuCIIITg mice compared with controls. Tissue culture studies with primary hepatocytes showed a modest increase in triglyceride, but not apo B or total protein, secretion in high expressor mice compared with controls. In summary, hypertriglyceridemia in HuCIIITg mice appears to result primarily from decreased tissue uptake of triglyceride-rich particles from the circulation, which is most likely due to increased apo CIII and decreased apo E on VLDL particles. the HuCIIITg mouse appears to be a suitable animal model of primary familial hypertriglyceridemia, and these studies suggest a possible mechanism for this common lipoprotein disorder.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1889
page 1889
icon of scanned page 1890
page 1890
icon of scanned page 1891
page 1891
icon of scanned page 1892
page 1892
icon of scanned page 1893
page 1893
icon of scanned page 1894
page 1894
icon of scanned page 1895
page 1895
icon of scanned page 1896
page 1896
icon of scanned page 1897
page 1897
icon of scanned page 1898
page 1898
icon of scanned page 1899
page 1899
icon of scanned page 1900
page 1900
Version history
  • Version 1 (November 1, 1992): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 9
  • Article usage
  • Citations to this article (353)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 7 patents
54 readers on Mendeley
See more details